Results 11 to 20 of about 68,686 (295)

Trypanosoma brucei brucei Induces Polymorphonuclear Neutrophil Activation and Neutrophil Extracellular Traps Release. [PDF]

open access: yesFront Immunol, 2020
Trypanosoma brucei brucei trypomastigotes are classical blood parasites of cattle, these stages might become potential targets for circulating polymorphonuclear neutrophils (PMN).
Grob D   +8 more
europepmc   +2 more sources

Cathepsin-L can resist lysis by human serum in Trypanosoma brucei brucei.

open access: yesPLoS Pathogens, 2014
Closely related African trypanosomes cause lethal diseases but display distinct host ranges. Specifically, Trypanosoma brucei brucei causes nagana in livestock but fails to infect humans, while Trypanosoma brucei gambiense and Trypanosoma brucei ...
Sam Alsford   +4 more
doaj   +2 more sources

Whole-Genome Sequencing of Trypanosoma brucei Reveals Introgression between Subspecies That Is Associated with Virulence [PDF]

open access: yesmBio, 2013
Human African trypanosomiasis is caused by two subspecies of Trypanosoma brucei. Trypanosoma brucei rhodesiense is found in East Africa and frequently causes acute disease, while Trypanosoma brucei gambiense is found in West Africa and is associated with
Ian Goodhead   +10 more
doaj   +5 more sources

Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign.

open access: yesPLoS Neglected Tropical Diseases, 2012
Human African Trypanosomiasis (HAT) is caused by two trypanosome sub-species, Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Drugs available for the treatment of HAT have significant issues related to difficult administration regimes ...
Melissa L Sykes   +7 more
doaj   +2 more sources

Feeder layer-free in vitro assay for screening antitrypanosomal compounds against Trypanosoma brucei brucei and T. b. evansi

open access: greenAntimicrobial Agents and Chemotherapy, 1989
A drug-susceptible Trypanosoma brucei brucei stock, a multidrug-resistant T. b. brucei stock, and a T. b. evansi stock resistant to two commercial trypanocides were adapted to a feeder layer-free culture system.
Ronald Kaminsky, Erich Zweygarth
openalex   +2 more sources

VSIG4‐Expressing Macrophages Contribute to Antiparasitic and Antimetastatic Responses in the Peritoneal Cavity [PDF]

open access: yesEuropean Journal of Immunology, Volume 55, Issue 5, May 2025.
Although VSIG4+ LPMs and VSIG4− LPMs are identical at the transcriptomic and surface proteomic level, VSIG4+ LPMs are superior phagocytes that protect against CRC peritoneal outgrowth and influence the early phase of T. brucei brucei infection. ABSTRACT Large peritoneal macrophages (LPMs) play a role as gatekeepers of peritoneal homeostasis by ...
Els Lebegge   +25 more
wiley   +2 more sources

Route of inoculation influences Trypanosoma congolense and Trypanosoma brucei brucei virulence in Swiss white mice. [PDF]

open access: yesPLoS ONE, 2019
Experiments on infections caused by trypanosomes are widely performed in Swiss white mice through various inoculation routes. To better understand the effect of route of trypanosome inoculation on disease outcomes in this model, we characterised the ...
Kariuki Ndungu   +8 more
doaj   +2 more sources

Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase [PDF]

open access: yesAntimicrobial Agents and Chemotherapy, 1990
A structural analog, 5'-([(Z)-4-amino-2-butenyl]methylamino)-5'-deoxy adenosine (MDL 73811), of decarboxy S-adenosyl-L-methionine, the product of the reaction catalyzed by S-adenosyl-L-methionine (AdoMet) decarboxylase (DC), was found to inhibit Trypanosoma brucei brucei AdoMet DC.
C. J. Bacchi   +7 more
openaire   +4 more sources

Overproduction and Characterization of Recombinant Soluble Trypanosoma brucei Phospholipase A2 [PDF]

open access: yesEngineering in Life Sciences, Volume 25, Issue 3, March 2025.
ABSTRACT Trypanosoma brucei phospholipase A2 (TbPLA2) is a validated drug target but the difficulty in expressing its soluble recombinant protein has limited its exploitation for drug and vaccine development for African and American trypanosomiases. We utilized recombinant deoxyribonucleic acid (DNA) technology approaches to express soluble TbPLA2 in ...
Oluwafemi Abiodun Adepoju   +9 more
wiley   +2 more sources

Differences between Trypanosoma brucei gambiense groups 1 and 2 in their resistance to killing by Trypanolytic factor 1 [PDF]

open access: yes, 2011
<p><b>Background:</b> The three sub-species of <i>Trypanosoma brucei</i> are important pathogens of sub-Saharan Africa. <i>T. b.
A Cooper   +77 more
core   +21 more sources

Home - About - Disclaimer - Privacy